An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 486 participants.
Also called NCT07365332
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 486 participants
- Sponsor
- Inhibikase Therapeutics
- Registry
-
NCT07365332
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, New Zealand, Portugal, South Korea, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07365332. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2029-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- Acronym
- IMPROVE-PAH
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- IKT-001
- Intervention (Drug)
- Placebo
- Lead sponsor
- Inhibikase Therapeutics
Record details
- Record id
cardio:ct-nct07365332- Content hash
1cc4b0a46145e10f66f6a1aed72d4a92f42c7b29f920378c02aeddad22aa1fb8